Patents by Inventor Craig Struble

Craig Struble has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12195799
    Abstract: The present invention provides processes for determining accurate risk probabilities for fetal aneuploidies. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: January 14, 2025
    Assignee: Ariosa Diagnostics, Inc.
    Inventors: Arnold Oliphant, Andrew Sparks, Eric Wang, Craig Struble
  • Patent number: 11795508
    Abstract: The present invention provides methods for non-invasive determination of sex in a fetus or of Y chromosomal frequency abnormalities—indicative of aneuploidy or sex mosaicisms in a fetus—by detecting and determining the relative contribution genetic sequences from the Y chromosome in view of the percent fetal contribution in a maternal mixed sample.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: October 24, 2023
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Craig Struble, Arnold Oliphant, Eric Wang
  • Publication number: 20230107747
    Abstract: The present invention provides processes for calculating phased genomic sequences of the fetal genome using fetal DNA obtained from a maternal sample. The processes and systems of the present invention utilize novel technological and computational approaches to detect fetal genomic sequences and determine the phased heritable genomic sequences. The invention could be used, e.g., to identify in utero deleterious mutations carried by the parents and inherited by a fetus within a particular heritable genomic region.
    Type: Application
    Filed: July 12, 2022
    Publication date: April 6, 2023
    Inventors: John Stuelpnagel, Craig Struble, Eric Wang
  • Publication number: 20230101627
    Abstract: The present invention provides assay systems and methods for determining the percent fetal contribution of cell-free DNA in a maternal sample from a pregnant female with an egg donor pregnancy. Further provided, are assay systems and methods for determining a statistical likelihood of the presence or absence of a fetal aneuploidy in a maternal sample using a determined percent fetal cell-free DNA in the sample.
    Type: Application
    Filed: August 5, 2022
    Publication date: March 30, 2023
    Inventors: Arnold Oliphant, Eric Wang, Craig Struble
  • Publication number: 20220372562
    Abstract: The present invention provides assay systems and methods for detection of copy number variation at one or more loci and polymorphism detection at one or more loci in a mixed sample from an individual.
    Type: Application
    Filed: April 1, 2022
    Publication date: November 24, 2022
    Inventors: Andrew Sparks, Craig Struble, Eric Wang, Arnold Oliphant
  • Patent number: 11441185
    Abstract: The present invention provides assay systems and methods for determining the percent fetal contribution of cell-free DNA in a maternal sample from a pregnant female with an egg donor pregnancy. Further provided, are assay systems and methods for determining a statistical likelihood of the presence or absence of a fetal aneuploidy in a maternal sample using a determined percent fetal cell-free DNA in the sample.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: September 13, 2022
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Arnold Oliphant, Eric Wang, Craig Struble
  • Patent number: 11404142
    Abstract: The present invention provides processes for calculating phased genomic sequences of the fetal genome using fetal DNA obtained from a maternal sample. The processes and systems of the present invention utilize novel technological and computational approaches to detect fetal genomic sequences and determine the phased heritable genomic sequences. The invention could be used, e.g., to identify in utero deleterious mutations carried by the parents and inherited by a fetus within a particular heritable genomic region.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: August 2, 2022
    Assignee: Roche Molecular Systems, Inc.
    Inventors: John Stuelpnagel, Craig Struble, Eric Wang
  • Publication number: 20220208298
    Abstract: This invention relates to a binomial calculation of copy number of data obtained from a mixed sample having a first source and a second source.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 30, 2022
    Inventors: Craig Struble, John Stuelpnagel
  • Publication number: 20220157400
    Abstract: The present invention provides methods for non-invasive determination of X and/or Y chromosomal abnormalities indicative of aneuploidy or sex mosaicisms in a maternal sample by detecting and determining the relative contribution of genetic sequences from the X chromosome and/or the Y chromosome in the maternal sample.
    Type: Application
    Filed: February 4, 2022
    Publication date: May 19, 2022
    Inventors: Craig Struble, Arnold Oliphant, Eric Wang
  • Patent number: 11299772
    Abstract: The present invention provides assay systems and methods for detection of copy number variation at one or more loci and polymorphism detection at one or more loci in a mixed sample from an individual.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: April 12, 2022
    Assignee: Ariosa Diagnostics, Inc.
    Inventors: Andrew Sparks, Craig Struble, Eric Wang, Arnold Oliphant
  • Patent number: 11289176
    Abstract: This invention relates to a binomial calculation of copy number of data obtained from a mixed sample having a first source and a second source.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: March 29, 2022
    Assignee: Ariosa Diagnostics, Inc.
    Inventors: Craig Struble, John Stuelpnagel
  • Patent number: 11270781
    Abstract: The present invention provides methods for non-invasive determination of X and/or Y chromosomal abnormalities indicative of aneuploidy or sex mosaicisms in a maternal sample by detecting and determining the relative contribution of genetic sequences from the X chromosome and/or the Y chromosome in the maternal sample.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: March 8, 2022
    Assignee: Ariosa Diagnostics, Inc.
    Inventors: Craig Struble, Arnold Oliphant, Eric Wang
  • Publication number: 20220002725
    Abstract: The present disclosure relates to compositions, methods, modules and automated, integrated instrumentation to enable nucleic acid-guided nuclease or nickase fusion editing in cells and correlating the edits to the resulting cellular nucleic acid profile. In some embodiments, methylated bases in a repair template are substituted for unmethylated bases in the cellular target genome and in some embodiments, unmethylated bases are substituted for methylated bases in the cellular target genome.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 6, 2022
    Inventors: Stephen Tanner, Michael Graige, Nandini Krishnamurthy, Craig Struble
  • Publication number: 20220002755
    Abstract: The present disclosure relates to compositions, methods, modules and automated integrated instrumentation to make auxiliary or ancillary edits—in addition to intended edits and immunizing edits—in cellular genomic nucleic acids in order to assess and improve nucleic acid-guided nuclease or nickase fusion editing.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 6, 2022
    Inventors: Stephen Tanner, Michael Graige, Craig Struble, Nandini Krishnamurthy, Andrea Halweg-Edwards, Bryan Leland, Simon Cawley, Joshua Shorenstein, Timothy Shaver
  • Publication number: 20210343361
    Abstract: The present invention provides processes for determining accurate risk probabilities for chromosome dosage abnormalities. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.
    Type: Application
    Filed: May 20, 2021
    Publication date: November 4, 2021
    Inventors: John Stuelpnagel, Ken Song, Arnold Oliphant, Craig Struble
  • Publication number: 20210202030
    Abstract: The present invention provides processes for determining accurate risk probabilities for chromosome dosage abnormalities. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 1, 2021
    Inventors: John Stuelpnagel, Ken Song, Arnold Oliphant, Craig Struble
  • Publication number: 20210189493
    Abstract: The present invention provides processes for determining accurate risk probabilities for fetal aneuploidies. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.
    Type: Application
    Filed: June 29, 2020
    Publication date: June 24, 2021
    Inventors: Arnold Oliphant, Andrew Sparks, Eric Wang, Craig Struble
  • Patent number: 11031095
    Abstract: The present invention provides processes for determining accurate risk probabilities for chromosome dosage abnormalities. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: June 8, 2021
    Assignee: Ariosa Diagnostics, Inc.
    Inventors: John Stuelpnagel, Ken Song, Arnold Oliphant, Craig Struble
  • Patent number: 10847250
    Abstract: This invention relates to a binomial calculation of copy number of data obtained from a mixed sample having a first source and a second source.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 24, 2020
    Assignee: Ariosa Diagnostics, Inc.
    Inventors: Craig Struble, John Stuelpnagel
  • Patent number: 10718024
    Abstract: The present invention provides processes for determining accurate risk probabilities for fetal aneuploidies. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: July 21, 2020
    Assignee: Ariosa Diagnostics, Inc.
    Inventors: Arnold Oliphant, Andrew Sparks, Eric Wang, Craig Struble